696 related articles for article (PubMed ID: 34021874)
1. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
2. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
3. Use of BTK Inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Practical Guidance.
St-Pierre F; Ma S
Blood Lymphat Cancer; 2022; 12():81-98. PubMed ID: 35911566
[TBL] [Abstract][Full Text] [Related]
4. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
[TBL] [Abstract][Full Text] [Related]
5. MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Ryan CE; Davids MS; Hermann R; Shahkarami M; Biondo J; Abhyankar S; Alhasani H; Sharman JP; Mato AR; Roeker LE
Future Oncol; 2022 Oct; 18(33):3689-3699. PubMed ID: 36102212
[TBL] [Abstract][Full Text] [Related]
6. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
7. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
Gu D; Li J; Miao Y
Expert Opin Pharmacother; 2022 Dec; 23(18):1979-1986. PubMed ID: 36329558
[TBL] [Abstract][Full Text] [Related]
8. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O; Ma S
Curr Hematol Malig Rep; 2023 Oct; 18(5):130-143. PubMed ID: 37278884
[TBL] [Abstract][Full Text] [Related]
9. Update on the management of relapsed/refractory chronic lymphocytic leukemia.
Bennett R; Seymour JF
Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673
[TBL] [Abstract][Full Text] [Related]
10. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
11. Frontline Therapy of CLL: Evolving Treatment Paradigm.
Boddy CS; Ma S
Curr Hematol Malig Rep; 2018 Apr; 13(2):69-77. PubMed ID: 29480432
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
13. Chronic Lymphocytic Leukemia (CLL): Biology and Therapy.
Siddiqi T
Cancer Treat Res; 2021; 181():133-149. PubMed ID: 34626359
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
15. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
16. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
Wierda WG; Brown J; Abramson JS; Awan F; Bilgrami SF; Bociek G; Brander D; Chanan-Khan AA; Coutre SE; Davis RS; Eradat H; Fletcher CD; Gaballa S; Ghobadi A; Hamid MS; Hernandez-Ilizaliturri F; Hill B; Kaesberg P; Kamdar M; Kaplan LD; Khan N; Kipps TJ; Ma S; Mato A; Mosse C; Schuster S; Siddiqi T; Stephens DM; Ujjani C; Wagner-Johnston N; Woyach JA; Ye JC; Dwyer MA; Sundar H
J Natl Compr Canc Netw; 2022 Jun; 20(6):622-634. PubMed ID: 35714675
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Markers in the Era of Targeted Therapies.
Kang S; Ahn IE
Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
[TBL] [Abstract][Full Text] [Related]
18. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies.
Rainone M; Siddiqi T
Curr Hematol Malig Rep; 2022 Feb; 17(1):39-45. PubMed ID: 35028825
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
Islam P
Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
[TBL] [Abstract][Full Text] [Related]
20. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]